Table 3.
Within-group differences by time point (N = 11).
| Outcome measure | Change in mean ± SD | Change in % | P-value |
|---|---|---|---|
| Distance walked (6 MWT), m | |||
| Week 3–Week 0 | 10.55 ± 28.00 | 9.25 | 0.449 |
| Week 6–Week 0 | 44.91 ± 49.16 | 39.4 | 0.003* |
| Week 12–Week 0 | 56.18 ± 63.84 | 49.3 | 0.007* |
| Week 12–Week 6 | 11.27 ± 26.92 | 7.09 | 0.213 |
| Week 24–Week 0 | 58.82 ± 80.37 | 51.6 | 0.013* |
| Week 24–Week 6 | 13.91 ± 46.76 | 8.75 | 0.789 |
| Week 24–Week 12 | 2.64 ± 32.01 | 1.55 | 0.790 |
| Gait speed (10 MWT), m/s | |||
| Week 3–Week 0 | 0.03 ± 0.08 | 9.34 | 0.182 |
| Week 6–Week 0 | 0.12 ± 0.15 | 33.7 | 0.016 |
| Week 12–Week 0 | 0.17 ± 0.21 | 45.9 | 0.018 |
| Week 12–Week 6 | 0.05 ± 0.07 | 9.19 | 0.082 |
| Week 24–Week 0 | 0.14 ± 0.24 | 37.8 | 0.086 |
| Week 24–Week 6 | 0.02 ± 0.14 | 3.13 | 0.878 |
| Week 24–Week 12 | −0.03 ± 0.09 | −5.56 | 0.153 |
| BBS score, /56 | |||
| Week 3–Week 0 | 2 ± 1 | 5.73 | 0.005* |
| Week 6–Week 0 | 3 ± 2 | 7.11 | 0.003* |
| Week 12–Week 0 | 5 ± 3 | 11.9 | 0.005* |
| Week 12–Week 6 | 2 ± 3 | 4.49 | 0.084 |
| Week 24–Week 0 | 2 ± 2 | 5.96 | 0.012 |
| Week 24–Week 6 | 0 ± 2 | −1.07 | 0.234 |
| Week 24–Week 12 | −3 ± 3 | −5.32 | 0.030 |
| FAC score | |||
| Week 3–Week 0 | 0 ± 1 | 4.35 | 0.317 |
| Week 6–Week 0 | 0 ± 1 | 6.52 | 0.180 |
| Week 12–Week 0 | 1 ± 1 | 19.57 | 0.063 |
| Week 12–Week 6 | 1 ± 0 | 12.2 | 0.083 |
| Week 24–Week 0 | 0 ± 1 | −4.35 | 0.705 |
| Week 24–Week 6 | 0 ± 1 | −10.2 | 0.458 |
| Week 24–Week 12 | 0 ± 1 | −20.0 | 0.102 |
6 MWT, 6 minute walk test; 10 MWT, 10 meter walk test; BBS, Berg Balance Scale; FAC, Functional Ambulation Category.
Wilcoxon Signed Rank test was performed.
*
Significant p < 0.007 (0.05/7 = 0.007).